PURPOSE: In this study, the contrasting properties of human serum albumin nanoparticles (HSA-NPs) loaded with gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) and coated with transferrin in MRI in mice are evaluated. PROCEDURES: HSA-NPs were conjugated with Gd-DTPA (Gd-HSA-NPs) and coupled with transferrin (Gd-HSA-NP-Tf). Mice underwent MRI before or after injection of Gd-DTPA, Gd-HSA-NP, or Gd-HSA-NP-Tf. RESULTS: All the studied contrast agents provided a contrast enhancement (CE) in the blood, heart muscle, and liver. Compared to Gd-DTPA, CE with HSA-NP was achieved at lower Gd doses. Gd-HSA-NP-Tf yielded significantly higher CE than Gd-HSA-NP in the skeletal muscle, blood, cardiac muscle, and liver (p < 0.05). Gd-HSA-NP-Tf achieved a significantly higher CE than Gd-HSA-NP and Gd-DTPA in the blood, cardiac muscle, and liver (p < 0.05). In the brain, only Gd-HSA-NP-Tf was found to cause a significant CE (p < 0.05). CONCLUSIONS: The Gd-HSA nanoparticles have potential as MRI contrast agents. In particular, Gd-HSA-NP-Tf has a potential as a specific contrast agent for the brain, while the blood-brain barrier is still intact, as well as in the heart, liver, and skeletal muscle.
PURPOSE: In this study, the contrasting properties of human serum albumin nanoparticles (HSA-NPs) loaded with gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) and coated with transferrin in MRI in mice are evaluated. PROCEDURES: HSA-NPs were conjugated with Gd-DTPA (Gd-HSA-NPs) and coupled with transferrin (Gd-HSA-NP-Tf). Mice underwent MRI before or after injection of Gd-DTPA, Gd-HSA-NP, or Gd-HSA-NP-Tf. RESULTS: All the studied contrast agents provided a contrast enhancement (CE) in the blood, heart muscle, and liver. Compared to Gd-DTPA, CE with HSA-NP was achieved at lower Gd doses. Gd-HSA-NP-Tf yielded significantly higher CE than Gd-HSA-NP in the skeletal muscle, blood, cardiac muscle, and liver (p < 0.05). Gd-HSA-NP-Tf achieved a significantly higher CE than Gd-HSA-NP and Gd-DTPA in the blood, cardiac muscle, and liver (p < 0.05). In the brain, only Gd-HSA-NP-Tf was found to cause a significant CE (p < 0.05). CONCLUSIONS: The Gd-HSA nanoparticles have potential as MRI contrast agents. In particular, Gd-HSA-NP-Tf has a potential as a specific contrast agent for the brain, while the blood-brain barrier is still intact, as well as in the heart, liver, and skeletal muscle.
Authors: Corine C Visser; Sanja Stevanović; L Heleen Voorwinden; Pieter J Gaillard; Daan J A Crommelin; Meindert Danhof; Albertus G De Boer Journal: J Drug Target Date: 2004-04 Impact factor: 5.121
Authors: E J Russell; T F Schaible; W Dillon; B Drayer; J LiPuma; A Mancuso; K Maravilla; H A Goldstein Journal: AJR Am J Roentgenol Date: 1989-04 Impact factor: 3.959
Authors: Lindsay K Hill; Joseph A Frezzo; Priya Katyal; Dung Minh Hoang; Zakia Ben Youss Gironda; Cynthia Xu; Xuan Xie; Erika Delgado-Fukushima; Youssef Z Wadghiri; Jin Kim Montclare Journal: ACS Nano Date: 2019-02-19 Impact factor: 15.881
Authors: E A Wallnöfer; G C Thurner; C Kremser; H Talasz; M M Stollenwerk; A Helbok; N Klammsteiner; K Albrecht-Schgoer; H Dietrich; W Jaschke; P Debbage Journal: Histochem Cell Biol Date: 2020-10-11 Impact factor: 4.304
Authors: Jessica Lohrke; Anna-Lena Frisk; Thomas Frenzel; Laura Schöckel; Martin Rosenbruch; Gregor Jost; Diana Constanze Lenhard; Martin A Sieber; Volker Nischwitz; Astrid Küppers; Hubertus Pietsch Journal: Invest Radiol Date: 2017-06 Impact factor: 6.016